<DOC>
	<DOCNO>NCT00320476</DOCNO>
	<brief_summary>Multiple Myeloma incurable disease . Recently develop targeted therapy give new hope patient multiple myeloma . Velcade combination agent currently trial newly diagnose patient , design sequential treatment VTD MPT patient transplant candidate . This would expect result maximal tumor control , thus , maximal survival benefit , equivalent high dose therapy autologous transplantation young population</brief_summary>
	<brief_title>VTD Followed By MPT Maintenance As First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates</brief_title>
	<detailed_description>The two effective non-cross resistant regimen , VTD MPT , apply sequentially patient multiple myeloma transplant candidate . This would expect result maximal tumor control , thus , maximal survival benefit , equivalent high dose therapy autologous transplantation young population</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Newly diagnose patient overt multiple myeloma candidate HDT/SCT old age ( &gt; 65 ) presence comorbid condition likely negative impact tolerability HDT/SCT . Sponsors review condition approval require . Presence measurable disease : serum Mprotein &gt; 1g/dL urine M protein &gt; 400mg/day Performance status £ ECOG 2 Expected survival ³ 6 month Pretreatment clinical laboratory value meet follow criterion within 14 day enrollment platelet ≥ 100 x 109/L hemoglobin ≥ 8 g/dL ( ≥ 4.96 mol/L ) Prior RBC transfusion recombinant human erythropoietin use allow ) absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal alanine aminotransferase ( ALT ) ≤ 2.5 time upper limit normal total bilirubin ≤ 1.5 time upper limit normal serum creatinine ≤ 3mg/dL correct serum calcium &lt; 14 mg/dL ( &lt; 3.5 mmol/L ) Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . Smoldering indolent myeloma History allergic reaction attributable compound contain boron mannitol Known hypersensitivity thalidomide dexamethasone Peripheral neuropathy neuropathic pain Grade 2 high define NCI CTCAE version 3 Uncontrolled severe cardiovascular disease , include MI within 6 month enrolment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis , cardiac ejection fraction &lt; 0.5 : Severe conduction disorder : Hypotension ( sit systolic BP ≤ 100 mmHg and/or sit diastolic BP ≤ 60 mmHg Sepsis Pregnancy breastfeed Uncontrolled Diabetes Mellitus Recurrent DVT pulmonary embolism Active ulcer detect gastroscopy Serious medical psychiatric illness likely interfere participation clinical study . Receipt extensive radiation therapy within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Multiple myeloma</keyword>
</DOC>